CGEN (Compugen) Other Current Liabilities: $3.32 Mil (As of Mar. 2026)


CGEN Compugen Ltd CGEN
60 GF Score
Price $2.28
GF Value $5.13
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Compugen Other Current Liabilities?

Compugen CGEN +6.79% 60 Other Current Liabilities is $3.32 Mil as of Mar. 2026. GuruFocus rates CGEN with a GF Score™ of 60/100 and a GF Value™ of $5.13 (Possible Value Trap). The stock has 4 warning signs investors should review.

Compugen's other current liabilities for the quarter that ended in Mar. 2026 was $3.32 Mil.

Compugen's quarterly other current liabilities increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($3.05 Mil) and increased from Dec. 2025 ($3.05 Mil) to Mar. 2026 ($3.32 Mil).

Compugen's annual other current liabilities declined from Dec. 2023 ($3.13 Mil) to Dec. 2024 ($3.07 Mil) and declined from Dec. 2024 ($3.07 Mil) to Dec. 2025 ($3.05 Mil).

Compugen Other Current Liabilities Related Terms

Compugen Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Compugen's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compugen Other Current Liabilities Chart

Compugen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.30 2.81 3.13 3.07 3.05

Compugen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 3.05 3.32
CGEN
60GF Score
Compugen Ltd CGEN
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compugen Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $3.32 Mil mean?
Compugen (CGEN) has a Other Current Liabilities of $3.32 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Compugen.
Is Compugen's Other Current Liabilities too high?
Compugen's current Other Current Liabilities is $3.32 Mil. Overall, Compugen has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Compugen's Other Current Liabilities compare to VRTX and REGN?
Compugen's Other Current Liabilities of $3.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Compugen. Compugen's current Other Current Liabilities is $3.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compugen stock overvalued right now?
Based on GuruFocus' analysis, Compugen (CGEN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.13, compared to a current price of $2.28 — trading 55.6% below its estimated fair value. The current Other Current Liabilities is $3.32 Mil. Compugen's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Compugen (CGEN), the current Other Current Liabilities is $3.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Compugen (CGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Compugen stock appears to be undervalued. The current stock price of $2.28 is trading 55.6% below its estimated GF Value™ of $5.13. GuruFocus considers Compugen to be Possible Value Trap.

Key valuation signals for CGEN:

  • Other Current Liabilities: $3.32 Mil
  • GF Value™: $5.13 vs. price of $2.28 (55.6% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Compugen Business Description

Other Exchanges CGEN:Israel
Address 26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
60GF Score

Get the complete analysis for CGEN

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.28
Price
$5.13
GF Value